Comparing Baseline Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps with and without Asthma in the AROMA Registry.

IF 3.7 3区医学 Q2 ALLERGY

Journal of Asthma and Allergy Pub Date : 2025-06-22 eCollection Date: 2025-01-01 DOI:10.2147/JAA.S519901

Anju T Peters, Enrico Heffler, Kathleen M Buchheit, Shigeharu Fujieda, Scott Nash, Changming Xia, Micah W Johnson, Mark Corbett, Lucia De Prado Gomez, Juby A Jacob-Nara, Amr Radwan

{"title":"Comparing Baseline Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps with and without Asthma in the AROMA Registry.","authors":"Anju T Peters, Enrico Heffler, Kathleen M Buchheit, Shigeharu Fujieda, Scott Nash, Changming Xia, Micah W Johnson, Mark Corbett, Lucia De Prado Gomez, Juby A Jacob-Nara, Amr Radwan","doi":"10.2147/JAA.S519901","DOIUrl":null,"url":null,"abstract":"Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease of the nose and paranasal sinuses. Asthma is a common coexisting condition, associated with more severe sinus disease and reduced quality of life. Treating patients with uncontrolled CRSwNP and coexisting asthma is currently challenging.Objective: To compare baseline characteristics and disease burden in patients with CRSwNP with and without coexisting asthma in AROMA.Methods: AROMA is a prospective global registry study recruiting adult patients with severe CRSwNP who initiate dupilumab and follows them for up to 36 months. All patients entering the registry were assessed for baseline demographics and disease characteristics.Results: As of February 2023, the study had enrolled 303 patients, with 210 (69.3%) patients reporting coexisting asthma. Of the patients with asthma, 11.0% reported ongoing oral/systemic corticosteroid use at baseline, and 29.0% had at least 1 severe asthma exacerbation in the year before screening.Conclusion: More than two-thirds of adults with CRSwNP who initiated dupilumab in AROMA have coexisting asthma. Of these patients, one-third reported at least 1 severe asthma exacerbation in the past year.","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"1041-1049"},"PeriodicalIF":3.7000,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12203015/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma and Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JAA.S519901","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease of the nose and paranasal sinuses. Asthma is a common coexisting condition, associated with more severe sinus disease and reduced quality of life. Treating patients with uncontrolled CRSwNP and coexisting asthma is currently challenging.

Objective: To compare baseline characteristics and disease burden in patients with CRSwNP with and without coexisting asthma in AROMA.

Methods: AROMA is a prospective global registry study recruiting adult patients with severe CRSwNP who initiate dupilumab and follows them for up to 36 months. All patients entering the registry were assessed for baseline demographics and disease characteristics.

Results: As of February 2023, the study had enrolled 303 patients, with 210 (69.3%) patients reporting coexisting asthma. Of the patients with asthma, 11.0% reported ongoing oral/systemic corticosteroid use at baseline, and 29.0% had at least 1 severe asthma exacerbation in the year before screening.

Conclusion: More than two-thirds of adults with CRSwNP who initiated dupilumab in AROMA have coexisting asthma. Of these patients, one-third reported at least 1 severe asthma exacerbation in the past year.

查看原文本刊更多论文

在AROMA登记中比较慢性鼻窦炎合并鼻息肉合并和不合并哮喘患者的基线特征。

背景：慢性鼻窦炎伴鼻息肉（CRSwNP）是一种主要的鼻和副鼻窦2型炎症性疾病。哮喘是一种常见的共存疾病，与更严重的鼻窦疾病和生活质量下降有关。治疗不受控制的CRSwNP和共存哮喘患者目前具有挑战性。目的：比较伴有和不伴有哮喘的CRSwNP患者的基线特征和疾病负担。方法：AROMA是一项前瞻性全球注册研究，招募接受dupilumab治疗的严重CRSwNP成年患者，并对其进行长达36个月的随访。所有进入登记处的患者都进行了基线人口统计学和疾病特征评估。结果：截至2023年2月，该研究纳入了303例患者，其中210例（69.3%）患者报告共存哮喘。在哮喘患者中，11.0%报告在基线时正在口服/全身使用皮质类固醇，29.0%在筛查前一年至少有一次严重哮喘发作。结论：超过三分之二的CRSwNP成人患者在AROMA中开始使用dupilumab时并发哮喘。在这些患者中，三分之一报告在过去一年中至少有一次严重哮喘发作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Asthma and Allergy Medicine-Immunology and Allergy

CiteScore

5.30

自引率

6.20%

发文量

185

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. Although the main focus of the journal will be to publish research and clinical results in humans, preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies.